Effect of Genetic Variants on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Involvement of ABCG2, SLCO1B1 and NAT2
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms26010260 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Eva González-Iglesias und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IIS-Princesa), 28006 Madri…. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily G, Member 2, Rosuvastatin Calcium, Liver-Specific Organic Anion Transporter 1, Neoplasm Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Comunidad de Madrid, Universidad Autónoma de Madrid, Programa Investigo (NextGenerationEU funds of the Recovery and Resilience Facility).
Abstract (Originalsprache)
Statins are the primary drugs used to prevent cardiovascular disease by inhibiting the HMG-CoA reductase, an enzyme crucial for the synthesis of LDL cholesterol in the liver. A significant number of patients experience adverse drug reactions (ADRs), particularly musculoskeletal problems, which can affect adherence to treatment. Recent clinical guidelines, such as those from the Clinical Pharmacogenetics Implementation Consortium (CPIC) in 2022, recommend adjusting rosuvastatin doses based on genetic variations in the ABCG2 and SLCO1B1 genes to minimize ADRs and improve treatment efficacy. Despite these adjustments, some patients still experience ADRs. So, we performed a candidate gene study to better understand the pharmacogenetics of rosuvastatin. This study included 119 healthy volunteers who participated in three bioequivalence trials of rosuvastatin alone or in combination with ezetimibe at the Clinical Trials Unit of the Hospital Universitario de La Princesa (UECHUP). Participants were genotyped using a custom OpenArray from ThermoFisher that assessed 124 variants in 38 genes associated with drug metabolism and transport. No significant differences were observed according to sex or biogeographic origin. A significant increase in t1/2 (pmultivariate(pmv) = 0.013) was observed in the rosuvastatin plus ezetimibe trial compared with the rosuvastatin alone trials. Genetic analysis showed that decreased (DF) and poor function (PF) volunteers for the ABCG2 transporter had higher AUC∞/DW (adjusted dose/weight), AUC72h/DW and Cmax/DW compared to normal function (NF) volunteers (pmv< 0.001). DF and PF volunteers for SLCO1B1 showed an increase in AUC72h/DW (pmv = 0.020) compared to increased (IF) and NF individuals. Results for ABCG2 and SLCO1B1 were consistent with the existing literature. In addition, AUC∞/DW, AUC72h/DW and Cmax/DW were increased in intermediate (IA) and poor (PA) NAT2 acetylators (pmv = 0.001, pmv< 0.001, pmv< 0.001, respectively) compared to rapid acetylators (RA), which could be associated through a secondary pathway that was previously unknown.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IIS-Princesa), 28006 Madrid, Spain.
- Pharmacology Department, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), 28029 Madrid, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.
ORCID-Profile: Eva González-Iglesias, Manuel Román, Gina Mejía-Abril, Antía Gómez-Fernández, Paula Soria-Chacartegui, Francisco Abad-Santos
Förderung
- Comunidad de Madrid
- Universidad Autónoma de Madrid
- Programa Investigo (NextGenerationEU funds of the Recovery and Resilience Facility)
- Instituto de Salud Carlos III
- AP-PriME projects
Zitieren
APA
González-Iglesias, E., Méndez-Ponce, C., Ochoa, D., Román, M., Mejía-Abril, G., Martín-Vilchez, S., de Miguel, A., Gómez-Fernández, A., Rodríguez-Lopez, A., Soria-Chacartegui, P., Abad-Santos, F., & Novalbos, J. (2024). Effect of Genetic Variants on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Involvement of ABCG2, SLCO1B1 and NAT2. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26010260
Vancouver
González-Iglesias E, Méndez-Ponce C, Ochoa D, Román M, Mejía-Abril G, Martín-Vilchez S, et al. Effect of Genetic Variants on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Involvement of ABCG2, SLCO1B1 and NAT2. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms26010260
BibTeX
@article{GonzlezIglesias2024,
author = {González-Iglesias, Eva and Méndez-Ponce, Clara and Ochoa, Dolores and Román, Manuel and Mejía-Abril, Gina and Martín-Vilchez, Samuel and de Miguel, Alejandro and Gómez-Fernández, Antía and Rodríguez-Lopez, Andrea and Soria-Chacartegui, Paula and Abad-Santos, Francisco and Novalbos, Jesús},
title = {Effect of Genetic Variants on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Involvement of ABCG2, SLCO1B1 and NAT2},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms26010260}
}
EUVIMED